Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers

Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers

HER2-positive (HER2+) breast cancer is defined by <i>HER2</i> oncogene amplification on chromosome 17q12 and accounts for 15–20% population of breast-cancer patients. Therapeutic anti-HER2 antibody such as trastuzumab is used as the first-line therapy for HER2-positive breast cancers. Ho...

Full description

Bibliographic Details
Main Authors: Ratnakar Reddy Kuchukulla, Injeoung Hwang, Sang Won Park, Sojeong Moon, Suhn Hyung Kim, Sumin Kim, Hwan Won Chung, Mi-Jung Ji, Hyun-Mee Park, Gu Kong, Wooyoung Hur
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceuticals
Subjects:
HER2-positive breast cancer
trastuzumab-resistance
CDK12 inhibitor
cyclinK degrader
2,6,9-trisubstituted purine
Online Access:https://www.mdpi.com/1424-8247/15/9/1041

Internet

https://www.mdpi.com/1424-8247/15/9/1041

Similar Items